This is crazy, page-24

Well it's trading at below the previous capital raising at 54c, and since then in no particular order:

- the results of the LuPin study have come out showing a material improvement in median overall survival vs the Novartis drug alone,
- the company has $30m cash once R&D is included which takes them well into 2022 when a potential drug buyout could occur once sufficient data has been generated
- GK sold a chunk of shares at 65c to institutional investors to fund the option exercise (but overall holding remains the same) - insto was willing to pay 65c to get in
- drug pipeline has been expanded with potent activity against pancreatic and gallbladder cancer cells
- IoNIC trial has commenced - potential the biggest TAM opportunity out of them all. Opdivo falling behind Keytruda on sales and needing to catch up
- NOXCOVID trial advanced, Veyonda shows potential to treat septic shock and patent application lodged
- Further study in combination with chemotherapy upcoming
- not to mention the impressive news coming out of Nyrada

Did I miss anything??

So if anything - it beggars belief than you can buy the company's stock cheaper now with all this new information versus what the capital raising was done late last year.

(And from my limited experience most biotech CEOs hype up their stocks)

There's definitely risk here but I'm just pointing out there's real value imo ar these levels.